

# Michael H Davidson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2079960/publications.pdf>

Version: 2024-02-01

111  
papers

6,168  
citations

76326

40  
h-index

69250

77  
g-index

112  
all docs

112  
docs citations

112  
times ranked

6406  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. <i>BMC Nephrology</i> , 2022, 23, 34.   | 1.8 | 4         |
| 2  | Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 443-460.   | 5.0 | 5         |
| 3  | Recent advances and emerging therapies in management of dyslipidemias. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 419-424.   | 4.9 | 3         |
| 4  | How I treat statin-associated side effects in an outpatient setting. <i>Future Cardiology</i> , 2021, 17, 1249-1260.   | 1.2 | 6         |
| 5  | Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. <i>Journal of Clinical Lipidology</i> , 2021, 15, 629-648.  | 1.5 | 69        |
| 6  | The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 200-204.   | 0.8 | 1         |
| 7  | Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 1196-1224. | 2.1 | 117       |
| 8  | Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. <i>Lipids in Health and Disease</i> , 2020, 19, 117.  | 3.0 | 3         |
| 9  | The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 54-61.  | 2.0 | 5         |
| 10 | Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 997-1007.e8.   | 1.5 | 6         |
| 11 | Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. <i>Cardiology Clinics</i> , 2018, 36, 277-285.  | 2.2 | 5         |
| 12 | Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. <i>European Heart Journal</i> , 2018, 39, 620-622.  | 2.2 | 13        |
| 13 | Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 321-330.   | 1.5 | 24        |
| 14 | Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 141-149.   | 0.8 | 4         |
| 15 | How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. <i>Current Cardiology Reports</i> , 2018, 20, 138.   | 2.9 | 5         |
| 16 | Ω-6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps. <i>Advances in Nutrition</i> , 2018, 9, 688-700.   | 6.4 | 73        |
| 17 | The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 898-907.e2.   | 1.5 | 44        |
| 18 | Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 815-825.           | 1.6 | 12        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 251-260.          | 2.2 | 1         |
| 20 | Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. <i>Journal of Clinical Lipidology</i> , 2017, 11, 739-748.  | 1.5 | 2         |
| 21 | The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 415-423.  | 1.5 | 44        |
| 22 | Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)®. <i>Patient</i> , 2017, 10, 321-334.  | 2.7 | 9         |
| 23 | The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 145-152.   | 3.1 | 21        |
| 24 | Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. <i>JAMA Internal Medicine</i> , 2016, 176, 1530.  | 5.1 | 1         |
| 25 | The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1442-1451.e4.  | 1.5 | 22        |
| 26 | Intensive statin therapy in India: Demonstrating efficacy and safety. <i>Indian Heart Journal</i> , 2016, 68, 756-757.   | 0.5 | 1         |
| 27 | The future of n-3 polyunsaturated fatty acid therapy. <i>Current Opinion in Lipidology</i> , 2016, 27, 570-578.  | 2.7 | 16        |
| 28 | Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 314-322. | 1.5 | 4         |
| 29 | Update on PCSK9 therapies for the treatment of dyslipidemia. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 87-95.   | 2.4 | 2         |
| 30 | Changing characteristics of statin-related cIMT trials from 1988 to 2006. <i>Atherosclerosis</i> , 2016, 246, 121-129.   | 0.8 | 3         |
| 31 | Time-related trends in variability of cIMT changes in statin trials. <i>Data in Brief</i> , 2016, 6, 530-541.  | 1.0 | 1         |
| 32 | Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. <i>Lipids in Health and Disease</i> , 2015, 14, 98.                      | 3.0 | 46        |
| 33 | Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis. <i>Clinical Lipidology</i> , 2015, 10, 305-312.  | 0.4 | 18        |
| 34 | Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.   | 0.9 | 311       |
| 35 | Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 41-50.  | 2.6 | 16        |
| 36 | Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. <i>Atherosclerosis</i> , 2015, 241, 92-99.   | 0.8 | 11        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. <i>EBioMedicine</i> , 2015, 2, 284.  | 6.1 | 2         |
| 38 | Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. <i>Current Atherosclerosis Reports</i> , 2015, 17, 72.   | 4.8 | 11        |
| 39 | Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1045-1054.  | 1.5 | 7         |
| 40 | Combination Therapy with Statins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 993-1006.  | 3.2 | 1         |
| 41 | Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2525-2540.   | 2.8 | 192       |
| 42 | Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2014, 126, 56-65.   | 2.0 | 11        |
| 43 | Comparison of the Lipid-Lowering Effects of Pitavastatin 4 mg Versus Pravastatin 40 mg in Adults With Primary Hyperlipidemia or Mixed (Combined) Dyslipidemia: A Phase IV, Prospective, US, Multicenter, Randomized, Double-blind, Superiority Trial. <i>Clinical Therapeutics</i> , 2014, 36, 1211-1222. | 2.5 | 22        |
| 44 | Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1298-1306.  | 2.4 | 59        |
| 45 | Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. <i>Journal of Clinical Lipidology</i> , 2014, 8, 94-106.  | 1.5 | 198       |
| 46 | Overcoming toxicity and side-effects of lipid-lowering therapies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 439-452.   | 4.7 | 41        |
| 47 | Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 1-10.   | 1.4 | 2         |
| 48 | Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. <i>Journal of Clinical Lipidology</i> , 2013, 7, 102-108.  | 1.5 | 34        |
| 49 | A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). <i>Clinical Therapeutics</i> , 2013, 35, 1400-1411.e3.  | 2.5 | 94        |
| 50 | The Efficacy of Colesevelam HCl in the Treatment of Heterozygous Familial Hypercholesterolemia in Pediatric and Adult Patients. <i>Clinical Therapeutics</i> , 2013, 35, 1247-1252.   | 2.5 | 18        |
| 51 | Omega-3 fatty acids. <i>Current Opinion in Lipidology</i> , 2013, 24, 467-474.  | 2.7 | 83        |
| 52 | Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. <i>Journal of Lipid Research</i> , 2013, 54, 467-472.   | 4.2 | 52        |
| 53 | Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. <i>Vascular Health and Risk Management</i> , 2013, 9, 563.  | 2.3 | 71        |
| 54 | Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 349-358.          | 2.6 | 14        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a Tj ETQp1 1 0.784314 rgBT  | 1.6 | 14        |
| 56 | Introduction. American Journal of Cardiology, 2012, 110, 1B-3B.   | 1.6 | 0         |
| 57 | Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist. American Journal of Cardiology, 2012, 110, 43B-49B.   | 1.6 | 29        |
| 58 | Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction. Cardiology Clinics, 2011, 29, 105-122.  | 2.2 | 10        |
| 59 | Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. Journal of Clinical Lipidology, 2011, 5, 141-151.   | 1.5 | 18        |
| 60 | Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.  | 1.5 | 235       |
| 61 | Introduction. American Journal of Cardiology, 2011, 108, 1B-2B.   | 1.6 | 5         |
| 62 | Cardiovascular Effects of Glucagonlike peptide-1 Agonists. American Journal of Cardiology, 2011, 108, 33B-41B.  | 1.6 | 65        |
| 63 | Novel developments in omega-3 fatty acid-based strategies. Current Opinion in Lipidology, 2011, 22, 437-444.  | 2.7 | 29        |
| 64 | Pioglitazone Versus Glimepiride on Coronary Artery Calcium Progression in Patients With Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1873-1876.  | 2.4 | 9         |
| 65 | Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. Journal of Clinical Lipidology, 2010, 4, 72-73.   | 1.5 | 0         |
| 66 | ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia. JAMA - Journal of the American Medical Association, 2009, 301, 1131.   | 7.4 | 128       |
| 67 | Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study. Clinical Therapeutics, 2009, 31, 2824-2838. | 2.5 | 43        |
| 68 | Introduction. American Journal of Cardiology, 2009, 104, 1E-2E.   | 1.6 | 2         |
| 69 | Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier. American Journal of Cardiology, 2009, 104, 52E-57E.   | 1.6 | 23        |
| 70 | Apolipoprotein Measurements: Is More Widespread Use Clinically Indicated?. Clinical Cardiology, 2009, 32, 482-486.  | 1.8 | 72        |
| 71 | Hypercholesterolemia Treatment Patterns and Low-Density Lipoprotein Cholesterol Monitoring in Patients with a Diagnosis of Atherosclerosis in Clinical Practice. American Journal of Medicine, 2009, 122, S51-S59.  | 1.5 | 11        |
| 72 | Medical management of patients before the incidence of a cardiovascular event. Journal of Clinical Lipidology, 2009, 3, 315-321.  | 1.5 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Introduction. American Journal of Cardiology, 2008, 101, S1-S2.  | 1.6 | 3         |
| 74 | Niacin Use and Cutaneous Flushing: Mechanisms and Strategies for Prevention. American Journal of Cardiology, 2008, 101, S14-S19.   | 1.6 | 70        |
| 75 | Introduction. American Journal of Cardiology, 2008, 101, S1-S2.  | 1.6 | 3         |
| 76 | Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. American Journal of Cardiology, 2008, 101, S51-S57.                                   | 1.6 | 133       |
| 77 | A Review of the Current Status of the Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and Metabolic Syndrome. American Journal of Cardiology, 2008, 102, 19L-27L.   | 1.6 | 24        |
| 78 | Retrospective Comparison of the Effectiveness of a Fenofibrate 145â€‰%mg Formulation Compared with the Standard 160â€‰%mg Tablet. Clinical Drug Investigation, 2008, 28, 615-623.  | 2.2 | 5         |
| 79 | Interrupting bile-acid handling and lipid and glucose control: Effects of colestevlam on glucose levels. Journal of Clinical Lipidology, 2008, 2, S29-S33.   | 1.5 | 5         |
| 80 | Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis, 2008, 197, 12-24.   | 0.8 | 470       |
| 81 | Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Review of Cardiovascular Therapy, 2008, 6, 391-409.   | 1.5 | 197       |
| 82 | Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus. Circulation, 2008, 117, 2123-2130.                        | 1.6 | 118       |
| 83 | Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opinion on Pharmacotherapy, 2008, 9, 1237-1248.  | 1.8 | 72        |
| 84 | Is LDL-C Passed Its Prime?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1582-1583.   | 2.4 | 19        |
| 85 | Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic Journal of Medicine, 2008, 75, 479-496.   | 1.3 | 7         |
| 86 | Targeting High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Disease. The American Heart Hospital Journal, 2007, 5, 210-216.   | 0.2 | 4         |
| 87 | Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clinical Therapeutics, 2007, 29, 1354-1367. | 2.5 | 371       |
| 88 | Rosuvastatin in Elderly Patients. Drugs and Aging, 2007, 24, 933-944.  | 2.7 | 7         |
| 89 | The use of colestevlam hydrochloride in the treatment of dyslipidemia: a review. Expert Opinion on Pharmacotherapy, 2007, 8, 2569-2578.  | 1.8 | 34        |
| 90 | Safety of Aggressive Lipid Management. Journal of the American College of Cardiology, 2007, 49, 1753-1762.   | 2.8 | 144       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Global Risk Management in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiology, 2007, 99, 41-50.  | 1.6 | 33        |
| 92  | Safety Considerations with Fibrate Therapy. American Journal of Cardiology, 2007, 99, S3-S18.   | 1.6 | 332       |
| 93  | High-Density Lipoprotein Metabolism: Potential Therapeutic Targets. American Journal of Cardiology, 2007, 100, S32-S40.   | 1.6 | 65        |
| 94  | Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. American Journal of Managed Care, 2007, 13 Suppl 10, S260-9.  | 1.1 | 4         |
| 95  | Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin). American Journal of Cardiology, 2006, 97, 223-228.   | 1.6 | 46        |
| 96  | Statin Safety: An Appraisal from the Adverse Event Reporting System. American Journal of Cardiology, 2006, 97, S32-S43.   | 1.6 | 98        |
| 97  | Statin Safety: An Assessment Using an Administrative Claims Database. American Journal of Cardiology, 2006, 97, S61-S68.  | 1.6 | 111       |
| 98  | Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. American Journal of Cardiology, 2006, 97, S89-S94.   | 1.6 | 370       |
| 99  | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opinion on Drug Safety, 2006, 5, 145-156.                           | 2.4 | 78        |
| 100 | New Concepts in Dyslipidemia in the Metabolic Syndrome and Diabetes. Metabolic Syndrome and Related Disorders, 2006, 4, 299-314.  | 1.3 | 4         |
| 101 | Differences between clinical trial efficacy and real-world effectiveness. American Journal of Managed Care, 2006, 12, S405-11.  | 1.1 | 33        |
| 102 | Management of Dyslipidemia in Patients with Complicated Metabolic Syndrome. American Journal of Cardiology, 2005, 96, 22-25.  | 1.6 | 27        |
| 103 | Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy. American Journal of Cardiology, 2005, 96, 3-13.   | 1.6 | 68        |
| 104 | Considerations in the Treatment of Dyslipidemia Associated With Chronic Kidney Failure and Renal Transplantation. Preventive Cardiology, 2005, 8, 244-249.  | 1.1 | 10        |
| 105 | Lipid Responses to a Dietary Docosahexaenoic Acid Supplement in Men and Women with Below Average Levels of High Density Lipoprotein Cholesterol. Journal of the American College of Nutrition, 2005, 24, 189-199. | 1.8 | 62        |
| 106 | Comparative effects of lipid-lowering therapies. Progress in Cardiovascular Diseases, 2004, 47, 73-104.   | 3.1 | 92        |
| 107 | Biologic therapies for dyslipidemia. Current Atherosclerosis Reports, 2004, 6, 69-72.   | 4.8 | 5         |
| 108 | Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opinion on Drug Safety, 2004, 3, 547-557.   | 2.4 | 71        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Combination therapy in the management of complex dyslipidemias. <i>Current Opinion in Lipidology</i> , 2004, 15, 423-431.                  | 2.7 | 25        |
| 110 | Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. <i>Postgraduate Medicine</i> , 2004, 116, 7-12. | 2.0 | 1         |
| 111 | Colesevelam Hydrochloride (Cholestagel). <i>Archives of Internal Medicine</i> , 1999, 159, 1893.   | 3.8 | 269       |